
WuXi Biologics (Cayman)
WXXWY | OTC
$11.68
-$0.29 (-2.42%)
At close: Nov 16, 2026, 3:59 PM ET
$11.68
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 3:46 PM ET
WuXi Biologics (Cayman) Company Profile
Company profile explainedCompany Profile
WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing. These services are provided to clients worldwide, with a significant presence in China, North America, and Europe. Beyond its core offerings, the company engages in various specialized activities, including offering expert advice on biopharmaceutical technology, managing international sales agreements, and developing and providing advanced testing solutions. It also handles sales and marketing efforts, supports clinical trials and production of biologics, produces and distributes medical goods, operates a contract development and manufacturing organization (CDMO) for vaccines, and supplies essential materials to the industry. Founded in 2014, WuXi Biologics is based in Wuxi, China, and maintains strategic alliances with partners such as ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc.
Key Executives
| Name | Position |
|---|---|
| Jian Dong | Chief Executive Officer of WuXi Vaccines |
| Zhisheng Chen | Chief Executive Officer & Executive Director |
| Lihua Yu | Chief Operating Officer & Senior Vice President |
| Ming Tu | Chief Financial Officer & Executive Vice President |
| Angus Scott Marshall Turner | Senior Vice President and Head of Global BD & Alliance Management |
| Ge Li | Founder & Chairman |
| He Wang | General Counsel, Chief Compliance Officer, SVP and Head of Legal & Compliance Department |
| Jijie Gu | Chief Scientific Officer & President of Global Biologics Research |
| Lina Fan | Senior Vice President & Head of Investor Relations |
| Xiaohui Liu | Executive VP & Chief Human Resources Officer |
| Xuejun Gu | CTO, Chief Client Officer, EVP of Global Biologics Development Department & Executive Director |
WuXi Biologics (Cayman)

| Country | China |
| IPO Date | Dec 18, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13,252 |
| CEO | Zhisheng Chen |
Contact Details
No. 108, Meiliang Road Wuxi,
JS 214092 China
Stock Details
| Ticker Symbol | WXXWY |
| Exchange | OTC |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 98260N108 |
| ISIN Number | US98260N1081 |
| SIC Code | n/a |
Recent News
- 3 months ago / seekingalpha.comWuXi Biologics (Cayman) Inc. (WXXWY) Q2 2026 Earnings Call Transcript
- 5 months ago / prnewswire.comWuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
- 5 months ago / prnewswire.comWuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
Add to Watchlist
Select watchlists to add or remove WXXWY